Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control

NCT00292877 is registered in ClinicalTrials.gov with St. Joseph's Healthcare Hamilton as lead sponsor.

NCT NCT00292877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00292877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control
Lead sponsor
St. Joseph's Healthcare Hamilton
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
July 31, 2008
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma